Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant
A.-K. Reuschl, L. Thorne, L. Zuliani Alvarez, M. Bouhaddou, K. Obernier, J. Hiatt, M. Soucheray, J. Turner, J. Fabius, G. T. Nguyen, D. Swaney, R. Rosales, K. M. White, P. Aviles, I. T. Kirby, , N. J. Krogan
This study evaluates the efficacy of host-directed therapies against the B.1.1.7 SARS-CoV-2 variant and finds similar antiviral activity compared to early-lineage SARS-CoV-2.
bioRxiv · Jan 24, 2021 · PreprintMicrobiology